Latest Commercial Sales News

Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.

Nickel Industries delivered US$125.9 million of adjusted EBITDA in the September quarter, led by a second consecutive record from the Hengjaya Mine. Its new ENC HPAL project reached 50% of nameplate capacity, but severe dry conditions delayed the next step: commercial sales.

Phoslock Environmental Technologies Limited (ASX:PET) reduced its September-quarter operating cash outflow to A$21,000 as sales receipts more than doubled from the previous quarter. The company has paused manufacturing in China after storage capacity was reached, while new lanthanum formulations and a first Phoslock 10 field trial move forward.

Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.

icetana AI has started FY27 with a sharp lift in recurring revenue and quarterly sales, while its Antara Core platform reached its first commercial deployment. The progress came alongside higher operating cash outflows and a $3.9 million cash balance.

Firebird Metals has produced 99.999% ultra-high-purity manganese sulphate at its Hunan pilot plant and started processing ore from its Western Australian Oakover project. The next test is whether the result can be independently replicated with Australian feedstock before the Perth demonstration plant begins commissioning in 2027.

Hazer Group has expanded its commercial pipeline through a paid Japanese utility study assessing hydrogen facilities of up to 300,000 tonnes per year, while its KBR alliance advances a standardised commercial-scale design. The company ended September with A$8.3 million in cash and reported A$12.9 million in pro-forma funding, but remains pre-revenue in the quarter.

Memphasys has reported record September-quarter invoiced revenue of A$211,000 as its Felix fertility device moves into more international markets. The commercial progress comes alongside A$3.5 million in funding, but the loan still requires shareholder approval for conversion into notes.

Aquirian has completed its Wubin Energetics Hub upgrade within budget and is preparing Drillforce to begin work at Brightstar Resources’ Lord Byron project under a contract valued at approximately $48 million over three years. The company also says Collar Keeper sales remain strong, while a biodegradable version moves towards commercialisation.

Metallium has completed a 12-hour campaign using three Flash Joule Heating reactors to process platinum-group-metal-bearing catalytic converter material under reactive chlorination conditions. The milestone advances the company’s scale-up program, but recovery results, product economics and feedstock grades remain unverified.

Pure Resources finished 2026 with $3.67 million in cash and no debt after raising $4.7 million, but its annual loss widened as it shifted from explorer to a Garnet Hills-led advanced materials platform. The company is now pursuing garnet abrasives, jumbo flake graphite and heavy rare earth recovery through US research and defence partnerships.

Energy Technologies has reported a deeper FY2026 loss, collapsing revenue and a $22.65 million equity deficiency, with its auditor flagging material uncertainty over the group’s ability to continue as a going concern. A five-year laser optics licence offers a potential new revenue path, but it remains conditional on development and future commercial sales.